SPRR2A and neoplasm: While monotherapies with either unarmed and armed retargeted HSVs were only moderately effective, the combined treatment of all variants with anti-PD1 led to a significant improvement in efficacy, and the percentage of complete tumour response comprised 60% (HSV), 75% (mIL-12), 50% (mGM-CSF), and 100% (mIL-12+mGM-CSF) of treated mice.